Extract

This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.

Inclusion criteria

• Diabetes Mellitus, Type 2

Country

• Canada
• Greece
• India
• Philippines
• Thailand
• Ukraine
• United States

Links

• nct
• ictrp